YNT-185
Based on 1 publication(s) in Google Scholar
YNT-185 is a nonpeptide, selective orexin type-2 receptor (OX2R) agonist, with EC50s of 0.028 and 2.75 μM for OX2R and OX1R, respectively. YNT-185 ameliorates narcolepsy-cataplexy symptoms in mouse models.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 98.46%
- CAS. Nr.: 1804978-81-1
- Formel: C33H37N5O5S
- Molecular Weight:615.74
-
Speicherung:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
GPCR/G Protein Compound Library
HY-L006
-
Neuronal Signaling Compound Library
HY-L013
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Highly Selective Activators Library
HY-L159
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Lactylation Compound Library
HY-L249
Publications Citing Use of MedChemExpress (MCE) YNT-185
MoreAlle Orexin Receptor (OX Receptor) Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO-K1 | EC50 |
0.028 μM
Compound: 30
|
Agonist activity at human OX2R expressed in CHOK1 cells by NFAT-response luciferase reporter gene assay
Agonist activity at human OX2R expressed in CHOK1 cells by NFAT-response luciferase reporter gene assay
|
[PMID: 26267383] |
| CHO-K1 | EC50 |
2.75 μM
Compound: 30
|
Agonist activity at human OX1R expressed in CHOK1 cells by calcium mobilization assay
Agonist activity at human OX1R expressed in CHOK1 cells by calcium mobilization assay
|
[PMID: 26267383] |
YNT-185 (300 nmol; i.c.v.) significantly increases wake time for 3 hours in a dose-dependent manner, accompanied by a decrease in NREM sleep time, in wild-type mice but not in OXRDKO mice[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male wild-type C57BL/6J mice[2]
-
Dosage:20, 40 mg/kg
-
Administration:I.p.
-
Result:Wake time was also significantly increased.
Chemical Information
-
CAS. Nr. 1804978-81-1
-
Appearance Solid
-
Molecular Weight 615.74
-
Formel C33H37N5O5S
-
Color Off-white to light yellow
-
SMILES
O=C(C1=CC(C2=CC=C(OC)C(S(=O)(NC3=CC=CC(NCCNC(C4=CC=CC=C4N(C)C)=O)=C3)=O)=C2)=CC=C1)N(C)C
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Brain Res
2025 Apr 15:149646. PMID: 40246189
Lösungsmittel & Löslichkeit
DMSO : 100 mg/mL (162.41 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (271 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Nagahara T, et al. Design and Synthesis of Non-Peptide, Selective Orexin Receptor 2 Agonists. J Med Chem. 2015;58(20):7931-7937. [Content Brief]
[2]. Irukayama-Tomobe Y, et al. Nonpeptide orexin type-2 receptor agonist ameliorates narcolepsy-cataplexy symptoms in mouse models. Proc Natl Acad Sci U S A. 2017;114(22):5731-5736. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.6241 mL | 8.1203 mL | 16.2406 mL | 40.6016 mL |
| 5 mM | 0.3248 mL | 1.6241 mL | 3.2481 mL | 8.1203 mL | |
| 10 mM | 0.1624 mL | 0.8120 mL | 1.6241 mL | 4.0602 mL | |
| 15 mM | 0.1083 mL | 0.5414 mL | 1.0827 mL | 2.7068 mL | |
| 20 mM | 0.0812 mL | 0.4060 mL | 0.8120 mL | 2.0301 mL | |
| 25 mM | 0.0650 mL | 0.3248 mL | 0.6496 mL | 1.6241 mL | |
| 30 mM | 0.0541 mL | 0.2707 mL | 0.5414 mL | 1.3534 mL | |
| 40 mM | 0.0406 mL | 0.2030 mL | 0.4060 mL | 1.0150 mL | |
| 50 mM | 0.0325 mL | 0.1624 mL | 0.3248 mL | 0.8120 mL | |
| 60 mM | 0.0271 mL | 0.1353 mL | 0.2707 mL | 0.6767 mL | |
| 80 mM | 0.0203 mL | 0.1015 mL | 0.2030 mL | 0.5075 mL | |
| 100 mM | 0.0162 mL | 0.0812 mL | 0.1624 mL | 0.4060 mL |
Powered by Bioz